Background:Gastrointestinal (GI) cancer encompasses a group of malignancies affecting the digestive tract and related organs, including cancers of the colon, pancreas, stomach, liver, and esophagus.
Instead, the research suggests that pairing 5-FU with drugs that enhance RNA damage could significantly improve outcomes for GI cancer patients. These insights are expected to pave the way for new ...
Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and gastrointestinal endoscopies, according to new clinical ...